Skip to main content

What Gilead's Quarter ended Sep 30, 2026 10-Q says: 6 signals

Gilead filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition announced, acquisition completed and bookings decline.

Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
14

Source: Autobound Signal API · 68 signals tracked for Gilead · updated

10-Q · latest 10

What Gilead's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 6 signals

    SEC EDGAR
  2. 10-Q

    Filed · 5 signals

    SEC EDGAR

Earlier 10-Q filings

Showing 10 of 14 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Gilead earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Facing complex logistics and reimbursement hurdles for new Yeztugo launch.The launch of the new injectable drug, Yeztugo, involves navigating complex payer coverage, reimbursement processes, and logistical challenges like "white bagging," creating a need for solutions that streamline patient journey management and provider integration.
Raised full-year revenue guidance, citing strong HIV portfolio performanceThe company increased its full-year HIV revenue growth guidance from 3% to 5% and raised the low end of its total product sales range. This financial outperformance and confidence indicates strong cash flow and budget availability for strategic initiatives.
Achieved record market share for key HIV drugs Biktarvy and DescovyFlagship HIV products Biktarvy and Descovy for PrEP reached record market shares of 52% and 45% respectively. This strong commercial momentum creates a need for investment in sales enablement, marketing automation, and data analytics to defend and expand this leadership position.
Struggling to lower hurdles for community adoption of cell therapies.Despite expanding treatment centers, the company acknowledges that 'we have more to do' to lower barriers for community adoption of its complex cell therapies. This indicates a need for solutions related to provider education, patient logistics, and simplifying treatment workflows.
Emphasizing disciplined operating expense management and business model leverage.Leadership repeatedly highlighted 'disciplined operating expense management' and 'operating expense discipline' as key contributors to financial performance. This signals a strong corporate mandate and appetite for technologies and services that can drive efficiency and reduce costs.
New liver disease drug Livdelzi achieved 35% sequential growthThe liver disease drug Livdelzi grew 35% sequentially, surpassing $100 million in quarterly sales for the first time. This rapid growth in a new franchise indicates strong market uptake and creates budget opportunities for solutions that can support and scale this high-performing product line.

Signal API · MCP

Track Gilead with the Signal API

One POST /v1/companies/enrich call with gilead.com returns Gilead 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Gilead 10-Q

When did Gilead file its latest 10-Q?
Gilead filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Aug 6, 2026.
What did Gilead disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: Gilead completed acquisitions of Arcellx for $7.0B, Tubulis for $3.1B, and Ouro Medicines
What did Gilead say on its recent earnings calls?
Q3 FY2025: Facing complex logistics and reimbursement hurdles for new Yeztugo launch. (dated Oct 30, 2025).
Where can I read Gilead's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/gild-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →